[HTML][HTML] Renal intrinsic cells remodeling in diabetic kidney disease and the regulatory effects of SGLT2 Inhibitors
W Guo, H Li, Y Li, W Kong - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Diabetic kidney disease (DKD) is a prevalent complication of diabetes and a major
secondary factor leading to end-stage renal disease. The kidney, a vital organ, is composed …
secondary factor leading to end-stage renal disease. The kidney, a vital organ, is composed …
Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease
T Gan, Y Song, F Guo, G Qin - Molecular Biology Reports, 2022 - Springer
Diabetic kidney disease (DKD), a severe microvascular complication of diabetes mellitus, is
the primary cause of end stage renal disease (ESRD). Sodium-glucose cotransporter 2 …
the primary cause of end stage renal disease (ESRD). Sodium-glucose cotransporter 2 …
Non-linear association of fasting C-peptide and uric acid levels with renal dysfunction based on restricted cubic spline in patients with type 2 diabetes: A real-world …
L Chen, Y Hu, Y Ma, H Wang - Frontiers in Endocrinology, 2023 - frontiersin.org
Background Previous studies had showed divergent findings on the associations of C-
peptide and/or uric acid (UA) with renal dysfunction odds in patients with type 2 diabetes …
peptide and/or uric acid (UA) with renal dysfunction odds in patients with type 2 diabetes …
Therapeutic potential of conditioned medium obtained from deferoxamine preconditioned umbilical cord mesenchymal stem cells on diabetic nephropathy model
Background The therapeutic potential of mesenchymal stem cells (MSCs)-derived
conditioned media (CM) can be increased after preconditioning with various chemical …
conditioned media (CM) can be increased after preconditioning with various chemical …
Comparative Safety Analysis of Empagliflozin in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease versus Normal Kidney Function: A Nationwide Cohort …
HY Jang, IW Kim, JM Oh - Pharmaceutics, 2023 - mdpi.com
Background: Empagliflozin has been shown to reduce cardiovascular morbidity and
mortality in patients with type 2 diabetes. Various research on its efficacy in patients with …
mortality in patients with type 2 diabetes. Various research on its efficacy in patients with …
Visceral adipose tissue and risk of diabetic nephropathy: A Mendelian randomization study
M Tao, G Zhou, J Liu, M He, X Luo, C Wang… - Diabetes Research and …, 2024 - Elsevier
Objective Previous observational studies have established a correlation between visceral
adipose tissue (VAT) and diabetic nephropathy (DN). However, the causality of this …
adipose tissue (VAT) and diabetic nephropathy (DN). However, the causality of this …
Understanding Proteinuria in Patients with Diabetic Kidney Disease and Progress of Drug Therapy from a New Perspective
R Zhang, Q Wang, X Zhou, Q Li, Z Dong, X Chen - 2023 - preprints.org
Diabetic kidney disease (DKD) is one of the leading causes of end-stage renal disease
worldwide and significantly increases the risk of premature death due to cardiovascular …
worldwide and significantly increases the risk of premature death due to cardiovascular …
Research progress of natural active compounds on improving podocyte function to reduce proteinuria in diabetic kidney disease
L Gong, R Wang, X Wang, J Liu, Z Han, Q Li, Y Jin… - Renal …, 2023 - Taylor & Francis
Diabetic kidney disease (DKD) is a primary cause of end-stage renal disease. Proteinuria is
a clinical indicator of the different stages of DKD, and podocyte injury is a major cause of …
a clinical indicator of the different stages of DKD, and podocyte injury is a major cause of …
[PDF][PDF] 糖尿病肾脏疾病的早期诊断
张丹艳， 丁凯月， 仰智璇， 孙林 - 临床内科杂志, 2023 - lcnkzz.com
糖尿病肾脏疾病的早期诊断 Page 1 [DOI]10.3969/j.issn.10019057.2023.06.0001 http://www.lcnkzz.com/cN/10.3969/j.issn.10019057.2023.06.001
·综述与讲座· 糖尿病肾脏疾病的早期诊断 张丹艳丁凯月仰智璇孙林 基金项目:国家自然科学基金 …
·综述与讲座· 糖尿病肾脏疾病的早期诊断 张丹艳丁凯月仰智璇孙林 基金项目:国家自然科学基金 …